2023 World Conference on Lung Cancer (Posters)-P2.01. Efficiency and Survival Data of Neoadjuvant PD-1 Inhibitor Combined With Chemotherapy in Potentially Resectable IIIA or IIIB NSCLC

P2.01. Efficiency and Survival Data of Neoadjuvant PD-1 Inhibitor Combined With Chemotherapy in Potentially Resectable IIIA or IIIB NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the efficacy and survival data of neoadjuvant PD-1 inhibitor combined with chemotherapy in potentially resectable stage IIIA or IIIB non-small cell lung cancer (NSCLC). The current standard treatment for stage III NSCLC has a disappointing 5-year survival rate of 40%. The addition of antibodies that block programmed death 1 (PD-1) protein to chemotherapy has shown promise in improving survival in patients with resectable NSCLC. Sintilimab, a PD-1 inhibitor, has demonstrated clinical benefit in various studies. This study aimed to assess the effects of adding Sintilimab to traditional neoadjuvant chemotherapy in potentially resectable stage IIIA or IIIB NSCLC, with the goal of improving the pathological response rate, disease-free survival, and overall survival.<br /><br />The study enrolled treatment-naive patients with potentially resectable NSCLC who received Sintilimab plus nab-paclitaxel and carboplatin before surgery, followed by adjuvant chemoimmunotherapy. Of the 30 patients enrolled, 20 underwent surgery. The overall response rate and disease control rate were 67.7% and 96.7%, respectively. All surgical cases achieved R0 resection, with 45% of patients experiencing a pathologic complete response and 65% achieving a major pathological response. The median follow-up time was 30.6 months, and the median disease-free survival and overall survival were not reached. The two-year disease-free survival rate was 74.6%. Common adverse events included myocardial enzyme elevation, interstitial pneumonia, and bronchopleural fistula.<br /><br />In conclusion, neoadjuvant Sintilimab plus chemotherapy appears to be a promising treatment option for potentially resectable stage IIIA or IIIB NSCLC. This approach may provide more opportunities for surgical resection and improve disease-free survival and overall survival in these patients.

Asset Subtitle

Kewei Ma

Meta Tag

Speaker Kewei Ma

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

neoadjuvant PD-1 inhibitor

chemotherapy

stage IIIA

stage IIIB

non-small cell lung cancer

NSCLC

Sintilimab

pathological response rate

disease-free survival

overall survival